AC Immune (ACIU) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$21.7M

Revenue (quarter)

$18.7M

Revenue growth (year over year)

+1036.58%

Gross profit (trailing twelve months)

$21.7M

Gross margin

100.00%

Net income (trailing twelve months)

−$54.1M

Net income (quarter)

$2.3M

Net income growth (year over year)

+108.69%

Net margin

−249.37%

Return on equity

−78.59%

EPS (trailing twelve months)

−$0.54

Book value per share

$0.43

P/E (trailing twelve months)

—

Price to book

5.61

Debt to assets

76.62%

Payout ratio

—

Dividend yield

—

Company profile

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

• Is AC Immune (ACIU) profitable?

  No. AC Immune reported a net loss of $54.1M over the trailing twelve months.

• How much revenue does AC Immune (ACIU) make?

  AC Immune generated $21.7M in revenue over the trailing twelve months, up 1036.58% year over year.

• How do I buy stock in AC Immune (ACIU)?

  ACIU trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.